Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
161
resultados
Última actualización
26/06/2026 [09:55:00]
Resumen de: AU2025321641A1
The present invention provides a use of lactoferrin in combination with ergothioneine in the preparation of a drug for preventing and/or treating Alzheimer's disease. Compared with the use of lactoferrin or ergothioneine alone, in the present invention, the combined use of lactoferrin and ergothioneine at a specific ratio as an active pharmaceutical ingredient can reduce cell damage caused by Aβ25-35, reduce the expression of a p-Tau protein, lower the oxidative stress level and regulate apoptosis, alleviate memory impairment and cognitive dysfunction, and can reduce Aβ deposition in mouse plasma.
Resumen de: WO2026114055A1
Provided are a hydroxymethyltransferase and a use of a cofactor or metabolic substrate thereof in preparation of drugs for treating neurodegenerative diseases. Specifically, a hydroxymethyl transfer reaction is performed on glycine residues in protein aggregates such as Poly-GA, Poly-GR, and TDP-43 by means of serine hydroxymethyltransferase 1 (SHMT1) and serine hydroxymethyltransferase 2 (SHMT2), so that the aggregates are degraded, thereby reducing pathological aggregation, and thus ameliorating the pathological condition of patients with neurodegenerative diseases such as ALS and FTD and delaying disease progression. A cofactor and a metabolic substrate of the hydroxymethyltransferase can promote the activity of the hydroxymethyltransferase, thereby enhancing the hydroxymethyl transfer effect on the aggregates such as Poly-GA, Poly-GR and TDP-43, and thus can also be used for treatment of the neurodegenerative diseases such as ALS and FTD.
Resumen de: WO2026117675A1
Methods for treating and preventing Parkinson's disease have been developed wherein allopregnanolone is administered to a human in need thereof in an amount between about 2 mg and about 6 mg, preferably 4 mg per dose. The methods include administering a dosage of from 2 mg to 6 mg, preferably 4 mg, to the subject once within a 24 hour period. The dosing is repeated every seven days, or less frequently.
Resumen de: WO2026112688A1
Disclosed herein are methods for treating a motor neuron disease such as amyotrophic lateral sclerosis (ALS) comprising administering mEphA4-Fc with an interval of greater than every week, for example administering mEphA4-Fc every two weeks, every three weeks, or every four weeks, and at a concentration of about 10 to about 40 mg/kg body weight of a subject.
Resumen de: WO2026112697A1
The present disclosure relates to a method of treating or ameliorating symptoms of a motor neurone disease and improving motor neuron survival in a subject, more specifically treating or ameliorating symptoms of amyotrophic lateral sclerosis (ALS) and related neurodegenerative disorders. The treatment method comprises administering a Janus kinase (JAK) inhibitor in combination with one or more compounds selected from a glutamate antagonist and an N-methyl-D-aspartate (NMDA) receptor antagonist, in particular baricitinib in combination with riluzole and/or memantine, and compositions and kits thereof for same.
Resumen de: WO2026114612A1
The present invention relates to compounds of formula (I) as TMEM175 modulators for reducing alpha-synuclein aggregation for the treatment of Parkinson's disease.
Resumen de: WO2025021908A1
The present invention relates to a composition comprising an estetrol component for use in the prevention and treatment of menopause-associated Alzheimer's disease symptoms. The composition described herein displays favorable properties when compared to existing estrogen-based compositions that aim to alleviate estrogen deficiency symptoms. Also described are related uses and methods of treatment comprising administration of the composition.
Resumen de: EP4751721A1
The present invention relates to a use of a novel compound for preventing, alleviating, or treating Parkinson's disease, the novel compound exhibiting an effect of inhibiting synuclein aggregation in a Parkinson's disease (PD) mouse model. As a result of histological analysis, it was confirmed that the loss of dopaminergic neurons was blocked by treatment with the novel compound. Therefore, the novel compound can be effectively utilized in the development of a therapeutic agent for Parkinson's disease.
Resumen de: MX2026002381A
Provided are a gene therapy vector for treating Parkinson's disease and a use thereof. Specifically, provided is an adeno-associated virus (AAV) vector for treating Parkinson's disease, which can simultaneously express functional tyrosine hydroxylase (TH), GTP-cyclohydrolase 1 (GCH1) and aromatic amino acid decarboxylase (AADC) to promote dopamine synthesis. Also provided are an AAV virus particle containing the AAV vector, a composition containing the AAV vector or the AAV virus particle, and uses of the AAV vector, the AAV virus particle and the composition in the preparation of drugs for preventing or treating Parkinson's disease.
Resumen de: MX2026005980A
The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's Disease. Such methods entail administering a pharmaceutical composition comprising an immunogenic fragment of Aβ capable of inducing a beneficial immune response in the form of antibodies to Aβ. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant.
Resumen de: AU2024380023A1
The present disclosure relates generally to the use of agents, such as oligonucleotides, to improve, increase, restore or retain the integrity of the blood brain barrier; and/or to reduce the deposition or accumulation of and/or promote the clearance of, amyloid-β. The disclosure also related to agents, such as oligonucleotides, that increase, promote or restore the level or amount of VE-cadherin in a cell, and are thus useful in the methods of the present disclosure. The present disclosure also relates to the use of such agents to treat diseases and conditions associated with damage to the blood brain barrier, including diseases and conditions associated with neuroinflammation and neurodegeneration, as well as diseases and conditions associated with amyloid-β deposition, including Alzheimer's disease (AD), Cerebral amyloid angiopathy (CAA), Lewy body dementia (LBD) and traumatic brain injury (TBI).
Resumen de: WO2026108046A1
Provided are a monoclonal antibody against a p-Tau217 protein and the use thereof. Specifically, provided is an antibody targeting a p-Tau217 protein or an antigen-binding fragment thereof. The provided antibody can specifically recognize and bind to a p-Tau217 protein without recognizing p-Tau181 and non-phosphorylated Tau proteins, and can be used in the preparation of a detection preparation or kit for diagnosing diseases associated with the p-Tau217 protein, such as Alzheimer's disease.
Resumen de: US20260144772A1
Pharmaceutical compositions comprising antioxidants as useful therapeutic agents for treatment of amyotrophic lateral sclerosis (ALS), and methods thereof, are disclosed. In particular, the present disclosure provides enteric capsules and intravenous (i.v.) drip of aspirin-mimetic antioxidant drugs in intervention of ALS.
Resumen de: WO2026112645A1
The present disclosure provides novel methods for treatment of patients with autophagy diseases by administering a prodrug of dexibuprofen, such as but not limited to dexibuprofen dimethylamino ethyl ester (mDex) or a pharmaceutically acceptable salt thereof and compositions comprising the same.
Resumen de: AU2026203567A1
The invention relates to methods for promoting SCFA production by gut microbiota by administering a liquid, water-based probiotic composition. The methods are particularly effective at promoting gut health. The invention further relates to methods of promoting intestinal barrier integrity, methods of promoting a tolerogenic gut phenotype, and methods 5 of treating Parkinson’s Disease. ay a y
Resumen de: WO2026112528A1
Among other things, the present disclosure provides oligonucleotide compositions and methods thereof. In some embodiments, oligonucleotides comprise various chemical modifications of sugars, nucleobases, and/or internucleotidic linkages and patterns thereof and are usefill for exon skipping. In some embodiments, the present disclosure provides technologies useful for skipping cryptic exons of stathmin-2(STMN2) transcripts. In some embodiments, the present disclosure provides technologies useful for modulating STMN2 transcript splicing. In some embodiments, the present disclosure provides methods for preventing or treating conditions, disorders or diseases including neurodegenerative diseases, e.g,, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
Resumen de: US20260147006A1
0000 The present invention provides a useful and efficient screening method for finding a cholinergic muscarinic M1 receptor positive allosteric modulator (M1PAM) with reduced cholinergic side effects. The present invention also provides a method for treating Alzheimer's disease and the like, a method for reducing cholinergic side effects, and the like which use M1PAM selected by the screening method and having a low α value, or the M1PAM and an acetylcholinesterase inhibitor.
Resumen de: AU2026203520A1
Abstract Provided are compounds, methods, and pharmaceutical compositions for increasing the amount or activity of STMN2 RNA in a cell or animal, and in certain embodiments increasing the amount of STMN2 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom of a neurodegenerative disease. Such symptoms include ataxia, neuropathy, synaptic dysfunction, deficits in cognition, and decreased longevity. Such neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), Alzheimer's disease (AD), and dementia with Lewy bodies (DLB). Abstract
Resumen de: US20260146249A1
The invention relates to the field of human genetics, more specifically to treatments for a disease or condition associated with an abnormal processing of the Amyloid Precursor Protein (APP), preferably familiar Alzheimer disease (FAD). The invention in particular relates to antisense oligonucleotides (AON's) that can be used for treating such diseases or conditions.
Resumen de: WO2026112233A1
Disclosed are substituted heterocyclic compounds of formula (I) and pharmaceutically acceptable salts thereof, which may be suitable for imaging tau aggregates, b-sheet aggregates, beta-amyloid aggregates or alpha-synuclein aggregates, and hence are useful in binding and imaging tau aggregates in Alzheimer's patients. More specifically, this invention relates to a method of using the compounds of formula (I) as tracers in positron emission tomography (PET) imaging to study tau deposits in brain in vivo to allow diagnosis of Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology. The disclosure further relates to a method of measuring clinical efficacy of therapeutic agents for Alzheimer's disease and other neurodegenerative diseases characterized by tau pathology.
Resumen de: EP4748839A1
0001 Provided are a compound represented by formula (1'), or a tautomer, stereoisomer or pharmaceutically acceptable salt thereof. The compound represented by formula (I') has a strong agonistic effect on GLP-1R, and can treat diseases such as diabetes, metabolic-associated fatty liver diseases, and Alzheimer's disease, or has a weight loss effect.
Resumen de: WO2025017499A1
Provided herein, inter alia, pharmaceutical formulations for oral administration of ROCK2 inhibitors (e.g., compound A). Also provided are methods for treating a neurodegenerative disease characterized by the degeneration of motor neurons, and particularly amyotrophic lateral sclerosis (ALS), the method comprising administering to the subject in need thereof a therapeutically effective amount of a ROCK2 inhibitor.
Resumen de: CZ2023279A3
The solution in question applies to the use of bis(phenylmethylene)cycloalkanones and their heterocyclic analogues with general formula I in human and veterinary medicine to treat the diseases caused by the presence of misfolded proteins in a cell, disbalance of protein homeostasis and proteotoxic stress, proteinopathy in general, particularly neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Parkinson disease (PD), Alzheimer disease (AD), Kennedy disease (KD), Huntington disease (HD), Creutzfeldt-Jakob disease (CJD), spinocerebellar ataxia (SCA), transthyretin familial amyloid polyneuropathy, dentatorubral–pallidoluysian atrophy, system- or organ-specific amyloidosis, as well as cystic fibrosis and diabetes.
Resumen de: KR20260075695A
본 발명의 PI3K(Phosphoinositide 3-kinase) 억제제를 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 약학적 조성물 및 이를 포함하는 파킨슨병의 예방 또는 치료용 약학적 제제와, 후보 약물의 파킨슨병 치료효과를 예측하는 방법에 의하여, 파킨슨병의 치료 및 최적의 치료효과를 갖는 후보 약물의 선정을 기대할 수 있다.
Nº publicación: EP4748385A1 27/05/2026
Solicitante:
ALKAHEST INC [US]
Alkahest, Inc.
Resumen de: EP4748385A1
Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as neurocognitive disorders.
BOPI
Sede Electrónica
